Roche Strikes Obesity Drug Licensing Deal Worth Up to $1.16 Billion
Roche entered a licensing agreement with Rona Therapeutics for its investigational obesity drug candidate, worth up to $1.16 billion, the Chinese biotech firm said Tuesday.
Chinese biotech firm Rona Therapeutics said on Tuesday that Swiss drugmaker Roche BX:RHO had entered into a licensing agreement for Rona’s investigational obesity drug candidate. 16 billion. Roche is seeking to enter the obesity drug market, which is dominated by Eli Lilly NYSE:LLY and Novo…